

Accelerated absorption of regular insulin administered via a vascularizing permeable microchamber implanted subcutaneously in diabetic *Rattus norvegicus*

1 Short title: Rapid insulin absorption via a subcutaneously implanted microchamber in *R. norvegicus*

2 **Leah V. Steyn¹, Delaney Drew¹, Demetri Vlachos¹, Barry Huey¹, Katie Cocchi¹, Nicholas D.**
3 **Price¹, Robert Johnson², Charles W. Putnam¹, and Klearchos K. Papas^{1,2*}**

4 ¹Institute for Cellular Transplantation, Department of Surgery, University of Arizona College of
5 Medicine-Tucson, University of Arizona, Tucson, AZ, USA

6 ²Procyon Technologies, LLC., Medical Research Building (Room 121), University of Arizona,
7 Tucson, AZ, USA

8 *Corresponding author

9 Email: kkpapas@surgery.arizona.edu (KPP)

10 **Keywords: insulin, diabetes, microchamber, subcutaneous, rat, absorption, vascularizing,**
11 **pharmacokinetics**

12 **Abstract**

13 In Type 1 diabetes patients, even ultra-rapid acting insulins injected subcutaneously reach
14 peak concentrations in 45 minutes or longer. The lag time between dosing and peak concentration, as
15 well as intra- and inter-subject variability, render prandial glucose control and dose consistency
16 difficult. We postulated that insulin absorption from subcutaneously implantable vascularizing
17 microchambers would be significantly faster than conventional subcutaneous injection. Male athymic
18 nude *R. norvegicus* rendered diabetic with streptozotocin were implanted with vascularizing
19 microchambers (single chamber; 1.5 cm² surface area per side; nominal volume, 22.5 μ L). Plasma
20 insulin was assayed after a single dose (1.5 U/kg) of diluted insulin human (Humulin®R U-100),
21 injected subcutaneously or via microchamber. Microchambers were also implanted in additional
22 animals and retrieved at intervals for histologic assessment of vascularity. Following conventional
23 subcutaneous injection, the mean peak insulin concentration was 22.7 (SD 14.2) minutes. By
24 contrast, when identical doses of insulin were injected via subcutaneous microchamber 28 days after
25 implantation, the mean peak insulin time was shortened to 7.50 (SD 4.52) minutes. Peak insulin
26 concentrations were similar by either route; however, inter-subject variability was reduced when
27 insulin was administered via microchamber. Histologic examination of tissue surrounding
28 microchambers showed mature vascularization on days 21 and 40 post-implantation. Implantable
29 vascularizing microchambers of similar design may prove clinically useful for insulin dosing, either
30 intermittently by needle, or continuously by pump including in “closed loop” systems, such as the
31 artificial pancreas.

33 **Introduction**

34 In response to perturbations of plasma glucose concentration and other physiologic cues, the
35 normal endocrine pancreas modulates its release of insulin (and other hormones); insulin, entering
36 the portal venous circulation in approximately five second pulses and longer oscillations, rapidly and
37 precisely maintains glucose homeostasis [1]. In Type 1 diabetes mellitus (T1DM), the endocrine
38 pancreas fails to produce insulin in sufficient quantities, if at all [2]. Although pharmacologic insulins
39 are a life-saving therapy, they fail to mimic the rapidity and precision of glucose modulation
40 conferred by the normal pancreas [3]. Consequently, despite insulin therapy, diabetic patients remain
41 vulnerable to a range of costly, long-term, disabling complications.

42 Pharmacologic insulins are most often injected into the subcutaneous (SC) tissue of the
43 abdominal wall or extremities; however, because of the relative avascularity of SC tissue [4], the
44 dispensed insulin - depending upon its formulation - may require an hour or longer to attain its peak
45 concentration in the blood [4]. This delay in absorption renders insulin therapy an exercise in
46 predictive dosing, especially when anticipating the substantial swings in blood glucose concentration
47 encountered during and following meals [5]. The lag time between SC dosing and achieving an
48 effective insulin concentration in the blood also blunts the precision otherwise afforded by
49 continuous glucose monitoring (CGM) devices, sophisticated dosing decision algorithms, precision
50 insulin pumps, open- or closed-loop systems, and the “artificial pancreas” [4, 6].

51 Efforts to accelerate absorption of insulin have pursued two general approaches: novel
52 formulations of pharmacologic insulins and altered routes of administration. One or more amino acid
53 changes of the insulin molecule itself [7-12] and/or the addition of chemicals [13] reduce the
54 tendency of native insulin to form multimeric complexes which first must dissociate into monomers

55 or dimers in order to be absorbed [14]. These modifications of pharmacologic insulin have yielded
56 only incremental increases in the rate of absorption (reviewed in [4, 15]). Consequently, ultra-rapid
57 insulins have not achieved wide-spread patient acceptance [4], in part because of increased drug costs
58 [15] and a greater frequency of injection site reactions [16].

59 The second approach – alternative routes of administration affording more rapid uptake of
60 insulin - have included intradermal microinjection [17] or “jet spray” [18, 19], intraperitoneal
61 instillation [20, 21], or the inhalation of specially formulated insulins [22, 23]. None of these
62 strategies has gained widespread clinical acceptance, in part because of unpredictable dosing,
63 increased complication rates, and patient hesitancy [24, 25].

64 Although the lag times between SC injection and peak time (T_{max}) have been somewhat
65 foreshortened by the development of “ultra-rapid acting insulins” [Faster aspart (Fiasp), 63 min,
66 URLj (Lyumjev), 57 min [15]], the subcutaneous route is beleaguered by a second confounding
67 problem: intra-patient variability of absorption of the specified dose [26-28] resulting in
68 unanticipated blood glucose effects. This variance between anticipated and actual effect upon blood
69 glucose concentration contributes to the incidence of both diabetic ketoacidosis (DKA) and
70 importantly, hypoglycemic episodes [6], especially in those individuals who are constitutively
71 “hypoglycemia unaware” [29, 30].

72 Unpredictable discrepancies between the intended and evinced biochemical effects of a
73 particular SC dose are multifactorial. The vascularity of the subcutaneous space is not homogenous
74 even within individuals [22, 31-35] and the SC composition is further altered by repeated injections
75 [36, 37]. In a 2018 review [38], the multitude of factors affecting absorption of SC insulin are
76 discussed in detail; they include, among many others: variations in the depth of needle penetration,
77 including inadvertent intramuscular injection; dislodged catheters or mechanical issues associated

78 with insulin pump infusion sets [39]; and seepage of drug from the injection site. It stands to reason
79 that intra-patient variability compounds inter-patient dosage algorithms; predictions and comparisons
80 are therefore fraught, requiring complex modeling [40, 41].

81 To address the challenges posed by lagging absorption of even ultra-fast insulins and the
82 inconsistency of intrasubject dosing, we evaluated in a diabetic *R. norvegicus* model, subcutaneously
83 implantable vascularizing microchambers, IVMs (Fig 1A). These microchambers – of various
84 footprints and capacities – are engineered of polytetrafluoroethylene membranes (PTFE) and have a
85 surface configuration which promotes angiogenic ingrowth; an inner membrane simultaneously
86 blocks host cells from entering and occupying the microchamber [42]. We report here that the IVM,
87 implanted in the SC space, accelerates the absorption of inexpensive regular human insulin,
88 achieving pharmacokinetic profiles potentially superior to ultra-rapid acting insulins. Importantly,
89 our data also suggest that the IVM improves consistency of insulin delivery, thereby potentially
90 avoiding hazardous deviations in blood glucose concentration.

91

92 **Fig 1. The Procyon implantable vascularizing microchamber (IVM) and an illustrative clinical**
93 **application.**

94 (A) The vascularizing, microchamber (depicted before implantation), fabricated of PTFE, has a
95 surface area per side of 1.5 cm² and a nominal volume of 22.5μL. (B) One potential clinical
96 application of the IVM is to couple it with an insulin pump. The *infusion set* connects the *insulin*
97 *pump* to the SC implanted *microchamber*; the IVM's *connection tubing* is fitted with a *heal in place*
98 *cuff* fabricated from material that promotes vascularization. (C) A schematic of the vascularized
99 microchamber, depicting the ingrowth of blood vessels to its surface and the flow of insulin from

100 within the microchamber, through the permeable membranes, and into the richly vascularized SC
101 space surrounding the IVM.

102

103 **Materials and methods**

104 **Experimental animals**

105 Male athymic nude *R. norvegicus* between 9 - 12 weeks of age and weighing 250 - 350 g were
106 purchased from Envigo (Livermore, CA, USA). Animals were housed for a seven-day
107 acclimatization period before initiating any experimental procedures. All experiments were
108 performed with the approval of, and in accordance with guidelines established by, the Institutional
109 Animal Care and Use Committee (IACUC) at The University of Arizona.

110 **Induction of diabetes**

111 To avoid endogenous insulin in subject rats from cross-reacting in the human insulin assays,
112 animals were rendered diabetic by a single intraperitoneal injection, 60 mg/kg, of streptozotocin
113 (Sigma-Aldrich, St. Louis, MO, USA). Blood glucose concentrations were monitored daily using a
114 Freestyle Lite Glucose Monitoring System (Abbott Diabetes Care Inc., Alameda, CA, USA). Rats
115 were considered diabetic when blood glucose concentrations greater than 200 mg/dL were recorded
116 on three consecutive days. Rats verified as diabetic were maintained with exogenous long-acting
117 insulin (Lantus, Sanofi-Aventis, Bridgewater, NJ, USA) throughout the study; maintenance insulin
118 treatment also serves to forestall insulin resistance [43]. Maintenance insulin therapy was suspended
119 for 24 hours prior to each insulin kinetics study.

120 **Implantation of vascularizing microchambers (IVMs)**

121 Two days after the initial insulin-kinetics assay two empty, 1.5cm² per side, single-chamber
122 (having a nominal internal volume of 22.5 µL), implantable vascularizing microchambers, IVMs
123 (Procyon Technologies LLC, Tucson, AZ, USA) (Fig 1A) were implanted subcutaneously on the
124 dorsal aspect of each rat.

125 **Insulin kinetics assays**

126 **Subcutaneous injection of human insulin**

127 The initial insulin kinetics assays were performed 7 days after STZ induction of diabetes.
128 Nonfasted rats received a single subcutaneous injection of insulin human, 1.5 U/kg (Humulin R;
129 Lilly, Indianapolis, IN, USA). Each dose of insulin was diluted in 0.5 mL of sterile saline (0.9%)
130 solution, then injected subcutaneously using a glass Hamilton syringe fitted with a 20-gauge sharp
131 needle.

132 **Blood sample collection**

133 Blood samples (150 µL) were collected from the tail vein before injection (time = 0), and at 5-,
134 15-, 30-, 60-, 90-, and 120-minutes following injection. Blood samples for insulin assays were stored
135 on ice in 1.5 mL centrifuge tubes with EDTA until separation of plasma by centrifugation at 13,300 x
136 g for 15 minutes at 4° C. Plasma samples were stored at -20° C.

137 **Administration of human insulin via subcutaneously implanted IVMs**

138 On day 28 post-implantation, each rat received a single dose of insulin human, Humulin R, 1.5
139 U/kg (Lilly, Indianapolis, IN, USA), diluted as described above. The insulin was then instilled into
140 one of the two IVMs via its port. Blood samples for plasma insulin were collected and processed as
141 described above.

142 **Analysis of rat plasma samples for human insulin concentration**

143 Plasma samples collected from each insulin kinetics assay were analyzed for human insulin
144 concentration using a commercial human insulin ELISA kit (Alpco, Salem, NH, USA). Samples
145 were run in duplicate. The ELISA kit has a detection range of 3.0-200 μ IU/mL and a sensitivity of
146 0.399 μ IU/mL. The measured insulin concentrations were converted from IU/mL to μ g/mL
147 according to the manufacturer's recommended conversion ratios of 1 IU of human insulin = 6nmol =
148 34.8 μ g of insulin.

149 **IVM retrieval and histopathology**

150 At the conclusion of the study (day 40), rats were euthanized, and the IVMs were retrieved for
151 histology. Additional specimens were obtained 7 and 21 days after implantation from rats in a cohort
152 not included in the insulin analyses reported herein. After removal, each IVM including its adherent
153 tissue was placed in 10% neutral buffered formalin for fixation, then processed for paraffin
154 embedding. Paraffin blocks were sectioned and 5 μ M slices were collected throughout the
155 microchamber. Sections were stained with hematoxylin and eosin and imaged with a Keyence BZ-
156 X710 microscope (Keyence Co, Osaka, Japan).

157 **Statistical analysis**

158 **Insulin kinetic curves**

159 The concentrations of human insulin in each rat were normalized to zero by simple subtraction
160 of the variance at $t = 0$ from all values for that animal. The insulin kinetic curves were created by
161 calculating the mean values and standard deviations at each time point. In several instances, complete
162 plasma insulin concentration data were not obtained for a given rat in a particular assay; if more than
163 three of the seven data points were unavailable, the subject was excluded from analysis. Data from
164 one animal in the subcutaneous injection (control) group was excluded from analysis on that basis.

165 **Peak insulin times and concentrations**

166 The mean peak times (T_{max}) and concentrations of the insulin kinetic assays were obtained as
167 follows: for each subject the greatest plasma insulin concentration was identified, and both the time
168 point (*e.g.*, 10 min) and the insulin concentration at that time point were tabulated. The mean and SD
169 for each category were then calculated. The two assays, subcutaneous injection at day -2, and IVM
170 administration on day 28, were compared by the unpaired, two-tailed, t-test. The full kinetic curves
171 were compared with the nonparametric Friedman's test [44]. Statistical tests were conducted with
172 GraphPad Prism version 9.4.1 for Windows (GraphPad Software, San Diego, California USA,
173 www.graphpad.com).

174 **Results**

175 **Insulin-kinetics study after subcutaneous (SC) injection in diabetic rats**

176 Five days after successful induction of STZ diabetes, rats were injected subcutaneously with
177 diluted human insulin (Humulin R), followed by blood sampling for plasma insulin concentration
178 over a two-hour period. Consonant with the extensive literature documenting inter-subject variability

179 of insulin absorption after SC injection, the individual insulin curves were quite variable in timing
180 and concentration between animals (Fig 2A), with no clear peak by visual inspection (Fig 2C). The
181 mean peak of plasma insulin – T_{max} – was calculated as 22.7 (n=11, SD 14.2, 95% CI 13.18 – 32.27)
182 min post-injection and the peak concentrations averaged 12.3 (SD 3.16) ng/ml (Table 1). In the
183 experiments described above, the Humulin R stock suspension was diluted in 500 uL sterile saline,
184 approximately a 100-fold dilution. Because the rate of insulin absorption directly correlates with the
185 concentration of mono- and dimers, dilution of the stock solution might seem to favor dissociation of
186 multimeric insulin [9, 14]. In another experiment we compared two concentrations – diluted versus
187 stock – of Humulin R insulin after SC injection. The plasma insulin curves did not vary significantly
188 between the two concentrations (unpublished data), confirming that dilution of Humulin R did not
189 *per se* affect its rate of absorption.

190

191 **Fig 2. Plasma insulin kinetics after either SC or IVM injection of regular insulin.**

192 Plasma concentrations of human insulin were collected over 120 minutes following either
193 subcutaneous injection (A,C) or instillation into subcutaneous IVMs 28 days after implantation (B,D)
194 of regular insulin human (Humulin R) in identical doses. Shown in A and B are the data for the
195 individual subjects in each group of rats; in C and D are the insulin kinetic curves generated by
196 plotting means and standard deviations (SD). N=11 rats in the SC injection group (one rat was
197 excluded from the analysis because of incomplete plasma insulin concentration data); N=12 rats in
198 the IVM group.

199

200 **Table 1. Mean peak times and concentrations of plasma insulin after subcutaneous or IVM**
201 **injection in diabetic rats of insulin human (1.5 U/kg body weight).**

	Subcutaneous injection	IVM injection on day 28
Number of subjects (n)	11	12
Body weight (g)	302.1 (SD 25.1)	364.9 (SD 29.6)
T_{max} (min)	22.7 (SD 14.2)	7.50 (SD 4.52) **
95% CI of T_{max} (min)	13.18 – 32.27	4.626 – 10.39
Insulin concentration (ng/ml)	12.3 (SD 3.16)	11.7 (SD 4.97) NS

202 Given are means, standard deviations (SD), and 95% Confidence Intervals (CI). Although the peak
203 concentrations are not significantly different (NS), the interval to peak concentration (T_{max}) was
204 significantly shorter (** p=0.0020, by the unpaired, two-tailed t test) when insulin was delivered via
205 microchamber.

206

207 **Insulin kinetics after administration via a subcutaneous microchamber**

208 The implantable vascularizing microchamber (IVM) by Procyon (Fig 1A) is designed to
209 provide a means for rapid, consistent absorption of insulin without repeated needle (or pen or pump
210 cannula) injections; it measures 1.5 cm² in surface area per side. Its surface is engineered to promote
211 rapid vascularization. Published reports suggested that to be effectively vascularized, subcutaneously
212 implanted devices typically require three to four weeks in mice [45, 46], two to four weeks in rats
213 [47], and two months or less in primates [48]. We therefore conducted the insulin kinetics assays at
214 28 days after implantation, anticipating mature vascularization by that time. Diluted insulin human

215 was instilled into the IVM at the same dose by body weight as in the SC injection control studies,
216 described above.

217 At 28 days after implantation, 10 of the 12 individual plasma insulin curves peaked just five
218 minutes after injection (Fig 2B), as did the mean value (Fig 2D). The T_{\max} for insulin (Table 1) was
219 calculated as 7.50 (SD 4.52, 95% CI 4.626–10.37) min versus 22.7 (SD 14.2) min with conventional
220 SC injection, a statistically significant difference ($p = 0.0020$, Table 1). Not only was uptake of
221 insulin from the microchamber accelerated but the inter-subject variability appeared reduced (Fig
222 2B); this was also attested by the standard deviations of the mean peak (Table 1) and of the early time
223 points of the insulin curve (Fig 2D). Together, the data at day 28 after implantation, indicate that
224 insulin absorption from the IVM is significantly accelerated with improved inter-subject consistency,
225 compared to conventional SC needle injection.

226 **Evidence of vascularization revealed by histopathology of retrieved**

227 **IVMs**

228 The peak insulin data presented in the preceding section strongly support the notion that
229 vascularization of the SC tissues surrounding and invading the vascularizing membranes of the
230 microchambers had matured by 28 days and had thereby facilitated the very rapid uptake of insulin.
231 If so, histologic evidence of blood vessels immediately adjacent to the microchambers is likewise
232 expected in the same time frame.

233 To examine this supposition, IVMs implanted subcutaneously in rats for 7, 21 and 40 days
234 were retrieved and examined histologically. Although the 1.5 cm² microchambers were identical to
235 the ones used for insulin kinetics studies, they had not been injected with insulin to avoid

236 confounding effects on morphology that might be induced by the diffusion of human insulin into the
237 surrounding rat subcutaneous tissues. At 7 days after implantation (Fig 3A) a few vessels can be
238 identified but by day 21, subcutaneous vessels in proximity to the vascularizing membranes are both
239 prominent and plentiful (Fig 3B). Images of subcutaneous tissue surrounding the microchambers at
240 40 days (Fig 3C-F) reveal the presence of mature vasculature structures with larger vessels quite
241 close to the inner membranes of the IVMs. There was no histologic evidence of fibrotic overgrowth,
242 even at the latest time point. Thus, the histopathology of explanted IVMs indicates that
243 vascularization begins soon after implantation; the numbers of blood vessels greatly increase by three
244 to about six weeks after implantation, an observation congruent with the increased rapidity of insulin
245 uptake on day 28.

246

247 **Fig 3. Histopathologic images of retrieved microchambers and the surrounding subcutaneous**
248 **tissues**

249 The images of H & E (hematoxylin and eosin)-stained sections, using 20X (A-C) and 40X (D-F)
250 objectives, of IVMs retrieved 7, 21 or 40 days after implantation. The arrows point to vascular
251 structures. For orientation purposes, the image in C is labeled to identify the *surrounding (SC) tissue*
252 and the *insulin delivery chamber*. The linear structure (gray) is the inner membrane of the IVM.

253

254 **Discussion**

255 Here we report that a small (1.5 cm² surface area per side), specially engineered PTFE,
256 vascularizing microchamber (Fig 1) implanted subcutaneously facilitates more rapid uptake of

257 insulin than conventional SC injection. The IVM recruits the growth of blood vessels which establish
258 a surrounding vasculature, which fully matures by about one month (Fig 3). Regular insulin human
259 (Humulin R), when instilled into the IVM 28 days after implantation, achieves peak plasma
260 concentrations significantly faster than an identical dose delivered by conventional SC injection, 7.50
261 versus 22.7 min (Fig 2, Table 1). Additionally, inter-subject variability was reduced (Fig 2A,B). We
262 therefore conclude that the subcutaneously implanted microchambers are functionally mature within
263 weeks, not months.

264 The subcutaneous space is favored for insulin injection for patient convenience: it is a large
265 space readily accessible for injection and easily examined for problems at the sites of skin
266 penetration. Physiologically, however, it is less than ideal; its vascularity is both sparse and
267 heterogenous. Moreover, repeated injections may generate inflammation and consequent fibrosis,
268 rendering the microenvironment even less conducive to absorption of injected insulin. Finally,
269 utilizing the SC space for insulin delivery currently requires repeated injections, by needle, pen or
270 pump, their frequency depending upon the chosen insulin formulation(s) and the means of injection.

271 The primary clinical scenario for which we envisage the IVM achieving clinical utility for
272 T1DM patients (Fig 1) is a conceptual extension of the experiments described in this report – namely,
273 implantation in diabetic patients to facilitate the very rapid uptake of regular insulin. One might argue
274 that accelerating absorption via an IVM is an unnecessary redundancy now that ultra-rapid acting
275 insulins are available. However, the very rapid peak plasma insulin concentrations achieved with
276 regular insulin via IVM more closely mimic the normal human pancreas and are likely superior to
277 even ultra-rapid acting insulins injected SC [16, 49, 50]. The insulin kinetic curves (Fig 2 B, D) are
278 compatible with an “inject-eat continuum” strategy: this would, first, synchronize the insulin peak
279 with the prandial requirement; and second, avoid the pitfalls of inopportune delays of a meal by

280 simply postponing the injection. As shown in Fig 1, an insulin pump is easily connected to an IVM,
281 ensuring rapid uptake of the pumped insulin; this would allow greater precision in dosing and rapid
282 uptake of prandial boluses. Other challenging clinical scenarios would likewise benefit from rapid
283 uptake of insulin and therefore better glucose control. One example is insulin therapy of diabetics
284 during pregnancy, where precise glucose homeostasis is vital to the well-being, both immediate and
285 long-term, of mother and fetus [51].

286 Another argument sometimes made is that rapid uptake of insulin confers more risk than
287 benefit, for example, by triggering hypoglycemic episodes. However, the clinical safety and efficacy,
288 especially in post-prandial control, of ultra-rapid acting insulins is now supported by many studies
289 [15, 16, 52, 53]. The factitious “too rapid” assertion also deflects the many advances in continuous
290 glucose monitoring (CGM) devices, insulin dosage-predicting algorithms, precision-dosing insulin
291 pumps, open and closed loop systems, and the “artificial pancreas” (AP) [6]. To this point, a recent,
292 comprehensive review of multiple input AP systems [54], identified two persistent challenges: lag
293 times in acquiring blood glucose concentration data, and delays in absorption of insulin from SC
294 depots. Our study is relevant to the latter concern, which echoes an earlier sentiment: for APs (and
295 similar approaches) to achieve their full potential, the “applied insulin should induce ideally an
296 instantaneous effect” [4]. The IVM potentially offers a clinical means of further closing the gap
297 between insulin dose and blood glucose response.

298 **Conclusion**

299 Regular insulin human instilled into SC implantable vascularizing microchambers (IVMs)
300 implanted 28 days previously in diabetic rats attains mean peak plasma insulin concentrations in 7.5
301 (SD 4.50) min, versus 22.7 (SD 14.2) min following conventional SC injection. Inter-subject

302 variability was likewise reduced. Histologically, mature vascularization was evident at 21 and 40
303 days after implantation, indicating that neovascularization surrounding the IVMs contributed to the
304 rapidity of insulin uptake. We suggest that the implantable vascularizing microchambers reported
305 herein have clinical potential for the painless, repetitive, reproduceable delivery of regular insulin
306 with an absorption rate potentially exceeding that of ultra-rapid acting insulins.

307 **Acknowledgements**

308 The authors wish to acknowledge Chan A. Ion and Jennifer Kitzmann-Miner for their assistance in
309 preparing graphic work.

310 **References**

- 311 1. Matveyenko AV, Liuwantara D, Gurlo T, Kirakossian D, Dalla Man C, Cobelli C, et al.
312 Pulsatile portal vein insulin delivery enhances hepatic insulin action and signaling. *Diabetes*.
313 2012;61(9):2269-79. Epub 20120611. doi: 10.2337/db11-1462. PubMed PMID: 22688333; PubMed
314 Central PMCID: PMC3425431.
- 315 2. Linsley PS, Greenbaum CJ, Nepom GT. Uncovering Pathways to Personalized Therapies in
316 Type 1 Diabetes. *Diabetes*. 2021;70(4):831-41. doi: 10.2337/db20-1185. PubMed PMID: 33741606;
317 PubMed Central PMCID: PMC3425431.
- 318 3. Kramer CK, Retnakaran R, Zinman B. Insulin and insulin analogs as antidiabetic therapy: A
319 perspective from clinical trials. *Cell Metab*. 2021;33(4):740-7. doi: 10.1016/j.cmet.2021.03.014.
320 PubMed PMID: 33826916.
- 321 4. Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. *J Diabetes Sci*
322 *Technol*. 2012;6(4):728-42. Epub 20120701. doi: 10.1177/193229681200600402. PubMed PMID:
323 22920797; PubMed Central PMCID: PMC3440142.
- 324 5. Luijck YM, van Bon AC, Hoekstra JB, Devries JH. Premeal injection of rapid-acting insulin
325 reduces postprandial glycemic excursions in type 1 diabetes. *Diabetes Care*. 2010;33(10):2152-5.
326 Epub 20100806. doi: 10.2337/dc10-0692. PubMed PMID: 20693354; PubMed Central PMCID:
327 PMC2945151.
- 328 6. Domingo-Lopez DA, Lattanzi G, L HJS, Wallace EJ, Wylie R, O'Sullivan J, et al. Medical
329 devices, smart drug delivery, wearables and technology for the treatment of Diabetes Mellitus. *Adv*
330 *Drug Deliv Rev*. 2022;185:114280. Epub 20220408. doi: 10.1016/j.addr.2022.114280. PubMed
331 PMID: 35405298.

- 332 7. Becker RH, Frick AD, Burger F, Scholtz H, Potgieter JH. A comparison of the steady-state
333 pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine,
334 and regular human insulin in healthy volunteers using the euglycemic clamp technique. *Exp Clin*
335 *Endocrinol Diabetes*. 2005;113(5):292-7. doi: 10.1055/s-2005-865637. PubMed PMID: 15926116.
- 336 8. Bode BW. Comparison of pharmacokinetic properties, physicochemical stability, and pump
337 compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine. *Endocr Pract*.
338 2011;17(2):271-80. doi: 10.4158/ep10260.Ra. PubMed PMID: 21134878.
- 339 9. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, et al. Monomeric insulins
340 obtained by protein engineering and their medical implications. *Nature*. 1988;333(6174):679-82. doi:
341 10.1038/333679a0. PubMed PMID: 3287182.
- 342 10. Mudaliar SR, Lindberg FA, Joyce M, Beerdsen P, Strange P, Lin A, et al. Insulin aspart (B28
343 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared
344 with regular human insulin in healthy nondiabetic subjects. *Diabetes Care*. 1999;22(9):1501-6. doi:
345 10.2337/diacare.22.9.1501. PubMed PMID: 10480516.
- 346 11. Sheldon B, Russell-Jones D, Wright J. Insulin analogues: an example of applied medical
347 science. *Diabetes Obes Metab*. 2009;11(1):5-19. doi: 10.1111/j.1463-1326.2008.01015.x. PubMed
348 PMID: 19120431.
- 349 12. Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA technology in the treatment of
350 diabetes: insulin analogs. *Endocr Rev*. 2001;22(5):706-17. doi: 10.1210/edrv.22.5.0442. PubMed
351 PMID: 11588149.
- 352 13. Kildegaard J, Buckley ST, Nielsen RH, Povlsen GK, Seested T, Ribel U, et al. Elucidating the
353 Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide. *Pharm Res*.
354 2019;36(3):49. Epub 20190211. doi: 10.1007/s11095-019-2578-7. PubMed PMID: 30746556;
355 PubMed Central PMCID: PMC6373292.
- 356 14. Brange J, Owens DR, Kang S, Vølund A. Monomeric insulins and their experimental and
357 clinical implications. *Diabetes Care*. 1990;13(9):923-54. doi: 10.2337/diacare.13.9.923. PubMed
358 PMID: 2226110.
- 359 15. Wong EY, Kroon L. Ultra-Rapid-Acting Insulins: How Fast Is Really Needed? *Clin Diabetes*.
360 2021;39(4):415-23. doi: 10.2337/cd20-0119. PubMed PMID: 34866783; PubMed Central PMCID:
361 PMC63316.
- 362 16. Heise T, Piras de Oliveira C, Juneja R, Ribeiro A, Chigutsa F, Blevins T. What is the value of
363 faster acting prandial insulin? Focus on ultra rapid lispro. *Diabetes Obes Metab*. 2022. Epub
364 20220519. doi: 10.1111/dom.14773. PubMed PMID: 35593434.
- 365 17. Narayan RJ. Transdermal delivery of insulin via microneedles. *J Biomed Nanotechnol*.
366 2014;10(9):2244-60. doi: 10.1166/jbn.2014.1976. PubMed PMID: 25992456.
- 367 18. Malone JJ, Lowitt S, Grove NP, Shah SC. Comparison of insulin levels after injection by jet
368 stream and disposable insulin syringe. *Diabetes Care*. 1986;9(6):637-40. doi:
369 10.2337/diacare.9.6.637. PubMed PMID: 3542456.
- 370 19. Pehling GB, Gerich JE. Comparison of plasma insulin profiles after subcutaneous
371 administration of insulin by jet spray and conventional needle injection in patients with insulin-
372 dependent diabetes mellitus. *Mayo Clin Proc*. 1984;59(11):751-4. doi: 10.1016/s0025-
373 6196(12)65585-2. PubMed PMID: 6387316.

- 374 20. Dirnena-Fusini I, Åm MK, Fougner AL, Carlsen SM, Christiansen SC. Physiological effects
375 of intraperitoneal versus subcutaneous insulin infusion in patients with diabetes mellitus type 1: A
376 systematic review and meta-analysis. *PLoS One*. 2021;16(4):e0249611. Epub 20210413. doi:
377 10.1371/journal.pone.0249611. PubMed PMID: 33848314; PubMed Central PMCID:
378 PMCPMC8043377.
- 379 21. van Dijk PR, Logtenberg SJ, Gans RO, Bilo HJ, Kleefstra N. Intraperitoneal insulin infusion:
380 treatment option for type 1 diabetes resulting in beneficial endocrine effects beyond glycaemia. *Clin*
381 *Endocrinol (Oxf)*. 2014;81(4):488-97. Epub 20140728. doi: 10.1111/cen.12546. PubMed PMID:
382 25041605.
- 383 22. Al-Tabakha MM. Future prospect of insulin inhalation for diabetic patients: The case of
384 Afrezza versus Exubera. *J Control Release*. 2015;215:25-38. Epub 20150726. doi:
385 10.1016/j.jconrel.2015.07.025. PubMed PMID: 26222134.
- 386 23. Boss AH, Petrucci R, Lorber D. Coverage of prandial insulin requirements by means of an
387 ultra-rapid-acting inhaled insulin. *J Diabetes Sci Technol*. 2012;6(4):773-9. Epub 20120701. doi:
388 10.1177/193229681200600406. PubMed PMID: 22920801; PubMed Central PMCID:
389 PMCPMC3440146.
- 390 24. Bally L, Thabit H, Hovorka R. Finding the right route for insulin delivery - an overview of
391 implantable pump therapy. *Expert Opin Drug Deliv*. 2017;14(9):1103-11. Epub 20161207. doi:
392 10.1080/17425247.2017.1267138. PubMed PMID: 27911116; PubMed Central PMCID:
393 PMCPMC5581917.
- 394 25. Spaan N, Teplova A, Stam G, Spaan J, Lucas C. Systematic review: continuous
395 intraperitoneal insulin infusion with implantable insulin pumps for diabetes mellitus. *Acta Diabetol*.
396 2014;51(3):339-51. Epub 20140305. doi: 10.1007/s00592-014-0557-3. PubMed PMID: 24595518.
- 397 26. Heinemann L. Variability of insulin absorption and insulin action. *Diabetes Technol Ther*.
398 2002;4(5):673-82. doi: 10.1089/152091502320798312. PubMed PMID: 12450450.
- 399 27. Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, et al. Lower within-subject
400 variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1
401 diabetes. *Diabetes*. 2004;53(6):1614-20. doi: 10.2337/diabetes.53.6.1614. PubMed PMID: 15161770.
- 402 28. Morrow L, Muchmore DB, Ludington EA, Vaughn DE, Hompesch M. Reduction in
403 intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-
404 administration with recombinant human hyaluronidase in healthy volunteers. *Diabetes Technol Ther*.
405 2011;13(10):1039-45. Epub 20110629. doi: 10.1089/dia.2011.0115. PubMed PMID: 21714645.
- 406 29. Cryer PE, Davis SN, Shamon H. Hypoglycemia in diabetes. *Diabetes Care*.
407 2003;26(6):1902-12. doi: 10.2337/diacare.26.6.1902. PubMed PMID: 12766131.
- 408 30. Fanelli CG, Porcellati F, Pampanelli S, Bolli GB. Insulin therapy and hypoglycaemia: the size
409 of the problem. *Diabetes Metab Res Rev*. 2004;20 Suppl 2:S32-42. doi: 10.1002/dmrr.514. PubMed
410 PMID: 15551297.
- 411 31. Han D, Rahimi E, Aramideh S, Ardekani AM. Transport and Lymphatic Uptake of
412 Biotherapeutics Through Subcutaneous Injection. *J Pharm Sci*. 2022;111(3):752-68. Epub 20211006.
413 doi: 10.1016/j.xphs.2021.09.045. PubMed PMID: 34624293.

- 414 32. Hildebrandt P. Subcutaneous absorption of insulin in insulin-dependent diabetic patients.
415 Influence of species, physico-chemical properties of insulin and physiological factors. *Dan Med Bull.*
416 1991;38(4):337-46. PubMed PMID: 1914533.
- 417 33. Hildebrandt P. Skinfold thickness, local subcutaneous blood flow and insulin absorption in
418 diabetic patients. *Acta Physiol Scand Suppl.* 1991;603:41-5. PubMed PMID: 1789128.
- 419 34. Hildebrandt PR, Vaag AA. Local skin-fold thickness as a clinical predictor of depot size
420 during basal rate infusion of insulin. *Diabetes Care.* 1993;16(1):1-3. doi: 10.2337/diacare.16.1.1.
421 PubMed PMID: 8422761.
- 422 35. Gradel AKJ, Porsgaard T, Brockhoff PB, Seested T, Lykkesfeldt J, Refsgaard HHF. Delayed
423 insulin absorption correlates with alterations in subcutaneous depot kinetics in rats with diet-induced
424 obesity. *Obes Sci Pract.* 2019;5(3):281-8. Epub 20190318. doi: 10.1002/osp4.326. PubMed PMID:
425 31275602; PubMed Central PMCID: PMC6587326.
- 426 36. Hajheydari Z, Kashi Z, Akha O, Akbarzadeh S. Frequency of lipodystrophy induced by
427 recombinant human insulin. *Eur Rev Med Pharmacol Sci.* 2011;15(10):1196-201. PubMed PMID:
428 22165682.
- 429 37. Radermecker RP, Piérard GE, Scheen AJ. Lipodystrophy reactions to insulin: effects of
430 continuous insulin infusion and new insulin analogs. *Am J Clin Dermatol.* 2007;8(1):21-8. doi:
431 10.2165/00128071-200708010-00003. PubMed PMID: 17298103.
- 432 38. Gradel AKJ, Porsgaard T, Lykkesfeldt J, Seested T, Gram-Nielsen S, Kristensen NR, et al.
433 Factors Affecting the Absorption of Subcutaneously Administered Insulin: Effect on Variability. *J*
434 *Diabetes Res.* 2018;2018:1205121. Epub 20180704. doi: 10.1155/2018/1205121. PubMed PMID:
435 30116732; PubMed Central PMCID: PMC6079517.
- 436 39. Kanapka LG, Lum JW, Beck RW. Insulin Pump Infusion Set Failures Associated with
437 Prolonged Hyperglycemia: Frequency and Relationship to Age and Type of Infusion Set During
438 22,741 Infusion Set Wears. *Diabetes Technol Ther.* 2022;24(6):396-402. Epub 20220223. doi:
439 10.1089/dia.2021.0548. PubMed PMID: 35104166.
- 440 40. García-Jaramillo M, Calm R, Bondia J, Vehí J. Prediction of postprandial blood glucose
441 under uncertainty and intra-patient variability in type 1 diabetes: a comparative study of three interval
442 models. *Comput Methods Programs Biomed.* 2012;108(1):224-33. Epub 20120605. doi:
443 10.1016/j.cmpb.2012.04.003. PubMed PMID: 22677264.
- 444 41. Zheng H, Nathan DM, Schoenfeld DA. Using a multi-level B-spline model to analyze and
445 compare patient glucose profiles based on continuous monitoring data. *Diabetes Technol Ther.*
446 2011;13(6):675-82. Epub 20110413. doi: 10.1089/dia.2010.0199. PubMed PMID: 21488799;
447 PubMed Central PMCID: PMC3101946.
- 448 42. Brauker JH, Carr-Brendel VE, Martinson LA, Crudele J, Johnston WD, Johnson RC.
449 Neovascularization of synthetic membranes directed by membrane microarchitecture. *J Biomed*
450 *Mater Res.* 1995;29(12):1517-24. doi: 10.1002/jbm.820291208. PubMed PMID: 8600142.
- 451 43. Nordquist L, Sjöquist M. Improvement of insulin response in the streptozotocin model of
452 insulin-dependent diabetes mellitus. Insulin response with and without a long-acting insulin
453 treatment. *Animal.* 2009;3(5):685-9. doi: 10.1017/s175173110800387x. PubMed PMID: 22444446.

- 454 44. Friedman M. The Use of Ranks to Avoid the Assumption of Normality Implicit in the
455 Analysis of Variance. *Journal of the American Statistical Association*. 1937;32(200):675-701. doi:
456 10.1080/01621459.1937.10503522.
- 457 45. Hussey AJ, Winardi M, Han XL, Thomas GP, Penington AJ, Morrison WA, et al. Seeding of
458 pancreatic islets into prevascularized tissue engineering chambers. *Tissue Eng Part A*.
459 2009;15(12):3823-33. doi: 10.1089/ten.TEA.2008.0682. PubMed PMID: 19558221.
- 460 46. Pepper AR, Pawlick R, Gala-Lopez B, MacGillivray A, Mazzuca DM, White DJ, et al.
461 Diabetes Is Reversed in a Murine Model by Marginal Mass Syngeneic Islet Transplantation Using a
462 Subcutaneous Cell Pouch Device. *Transplantation*. 2015;99(11):2294-300. doi:
463 10.1097/tp.0000000000000864. PubMed PMID: 26308506; PubMed Central PMCID:
464 PMC4623852.
- 465 47. Rafael E, Wernerson A, Arner P, Tibell A. In vivo studies on insulin permeability of an
466 immunoisolation device intended for islet transplantation using the microdialysis technique. *Eur Surg*
467 *Res*. 1999;31(3):249-58. doi: 10.1159/000008700. PubMed PMID: 10352353.
- 468 48. Sasikala M, Rao GV, Vijayalakshmi V, Pradeep R, Pothani S, Kumar PP, et al. Long-term
469 functions of encapsulated islets grafted in nonhuman primates without immunosuppression.
470 *Transplantation*. 2013;96(7):624-32. doi: 10.1097/TP.0b013e31829e26cf. PubMed PMID: 23883970.
- 471 49. Bolli GB, Porcellati F, Lucidi P, Fanelli CG, Owens DR. One-hundred year evolution of
472 prandial insulin preparations: From animal pancreas extracts to rapid-acting analogs. *Metabolism*.
473 2022;126:154935. Epub 20211108. doi: 10.1016/j.metabol.2021.154935. PubMed PMID: 34762931.
- 474 50. Owens DR, Bolli GB. The continuing quest for better subcutaneously administered prandial
475 insulins: a review of recent developments and potential clinical implications. *Diabetes Obes Metab*.
476 2020;22(5):743-54. Epub 20200203. doi: 10.1111/dom.13963. PubMed PMID: 31930670; PubMed
477 Central PMCID: PMC7187182.
- 478 51. Amigó J, Corcoy R. Type 1 diabetes and pregnancy: An update on glucose monitoring and
479 insulin treatment. *Endocrinol Diabetes Nutr (Engl Ed)*. 2022. Epub 20220701. doi:
480 10.1016/j.endien.2022.06.008. PubMed PMID: 35787359.
- 481 52. Avgerinos I, Papanastasiou G, Karagiannis T, Michailidis T, Liakos A, Mainou M, et al.
482 Ultra-rapid-acting insulins for adults with diabetes: A systematic review and meta-analysis. *Diabetes*
483 *Obes Metab*. 2021;23(10):2395-401. Epub 20210622. doi: 10.1111/dom.14461. PubMed PMID:
484 34105242.
- 485 53. De Block CEM, Van Cauwenberghe J, Bochanen N, Dirinck E. Rapid-acting insulin
486 analogues: Theory and best clinical practice in type 1 and type 2 diabetes. *Diabetes Obes Metab*.
487 2022. Epub 20220411. doi: 10.1111/dom.14713. PubMed PMID: 35403348.
- 488 54. Hettiarachchi C, Daskalaki E, Desborough J, Nolan CJ, O'Neal D, Suominen H. Integrating
489 Multiple Inputs Into an Artificial Pancreas System: Narrative Literature Review. *JMIR Diabetes*.
490 2022;7(1):e28861. Epub 20220224. doi: 10.2196/28861. PubMed PMID: 35200143; PubMed Central
491 PMCID: PMC8914747.




Figure 1










Figure 2




Day 7 (20x)




Day 21 (20x)




Day 40 (20x)



Day 40 (40x)



Day 40 (40x)



Day 40 (40x)

Figure 3